BlackRock Fund Advisors’s Cymabay Therapeutics CBAY Stock Holding History

BlackRock Fund Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$117K	Buy	67,554 +1,708	+3%	+$3.02K	﹤0.01%	3567
2016 Q3	$128K	Sell	65,846 -226	-0.3%	-$450	﹤0.01%	3571
2016 Q2	$115K	Buy	66,072 +16,061	+32%	+$33.3K	﹤0.01%	3634
2016 Q1	$68K	Sell	50,011 -3,964	-7%	-$4.91K	﹤0.01%	3750
2015 Q4	$91K	Buy	53,975 +1,961	+4%	+$3.2K	﹤0.01%	3751
2015 Q3	$101K	Buy	52,014 +14,180	+37%	+$38.6K	﹤0.01%	3699
2015 Q2	$102K	Buy	+37,834	New	+$155K	﹤0.01%	3733

Other funds holding CBAY

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlackRock Fund Advisors's CBAY Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Cymabay Therapeutics (CBAY) stake by 2.6% in Q4 2016, buying an estimated $3.02K and bringing the position to 67,554 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #3567.

BlackRock Fund Advisors first reported a position in CBAY in Q2 2015 and has held it in 7 quarters since. The position peaked at $128K in Q3 2016. 27 funds tracked by Wall St. Rank hold CBAY as of Q4 2016.

BlackRock Fund Advisors held 67,554 shares of Cymabay Therapeutics worth $117K as of Q4 2016.
BlackRock Fund Advisors bought 1,708 Cymabay Therapeutics shares in Q4 2016, an estimated $3.02K.
Cymabay Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3567 holding.
BlackRock Fund Advisors first reported a position in Cymabay Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Fund Advisors's Cymabay Therapeutics position peaked at $128K in Q3 2016.
27 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.